Certara

Overview

Certara is a publicly listed biosimulation and model-informed drug development (MIDD) platform (NASDAQ: CERT) used across discovery, development, regulatory approval, and market access. Its software stack includes Simcyp PBPK, Phoenix PK/PD (Phoenix WinNonlin), Pinnacle 21 data standards, Certara.AI, and D360, with model-informed work supporting 90%+ of FDA novel approvals annually. Arsenal Capital Partners holds approximately 22.8% of common stock with board nomination rights. Certara also operates a market access and HEOR consulting practice alongside its software business.

Certara is not a claims-data RWE vendor in the traditional Komodo, IQVIA, or HealthVerity sense. It belongs on the shortlist when the manufacturer needs biosimulation, pharmacometrics, regulatory-qualified modeling, model-informed dose justification, or HEOR work, not when the primary need is large-scale longitudinal claims or EHR cohort analytics. For claims and EHR depth, pair Certara with a dedicated RWD platform.

Real-World Evidence Capability Model

The framework below standardizes how Rx Almanac evaluates real-world-evidence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Certara is evaluated as a publicly listed biosimulation and model-informed drug development (MIDD) platform used across discovery, development, regulatory approval, and market access.

Capability	Buyer should compare	Certara readout
Data assets and linkage coverage	Claims, EHR, registry, lab, mortality, genomic, provider, and patient-level linkage breadth.	Not the use case. Certara is a modeling and simulation platform, not a longitudinal claims/EHR data owner; pair with a dedicated RWD vendor when patient-level depth is the central need.
Study design and causal inference	Protocol development, statistical methods, bias control, synthetic/external controls, and reproducibility.	Adjacent. Certara’s strength is pharmacometric and PBPK modeling; for causal inference on observational data, pair with an RWD-focused HEOR vendor.
Regulatory, HTA, and payer evidence packages	FDA, EMA, NICE/HTA, payer value dossiers, label expansion, and post-market evidence use cases.	Core regulatory evidence. Regulatory-qualified Simcyp tools used by FDA/EMA in evaluations; MIDD work supports 90%+ of FDA novel approvals annually; March 2026 FDA accepted Simcyp predictions for the Novartis asciminib NDA, replacing 10 separate human clinical trials.
Oncology, rare disease, and specialty depth	Fit for small populations, biomarkers, longitudinal oncology records, rare-disease cohorts, and specialty-drug endpoints.	Core oncology and rare-disease evidence. Therapy fit: Oncology, Rare Disease, Cell & Gene Therapy; biosimulation is particularly useful for rare-disease and pediatric programs where in-vivo data is limited.
Analytics platform and self-service workflow	User-facing software, cohort builders, query tools, dashboards, and analyst service model.	Core analytics workflow. Simcyp PBPK, Phoenix PK/PD, Pinnacle 21, Certara.AI, and D360 form the user-facing software stack; Certara IQ adds AI-powered QSP modeling.
Privacy, governance, and refresh cadence	HIPAA controls, de-identification, data rights, governance, update frequency, and auditability.	Confirm governance control in the RFP. Confirm software licensing terms, model-governance practices, and how Certara handles client-side data uploaded into its modeling environment.

Buyer Fit

• Evaluation trigger: Manufacturers needing biosimulation, pharmacometrics, MIDD, regulatory-qualified modeling, or HEOR consulting to support submissions, label expansion, or value dossiers.
• Best-fit buyers: Oncology, rare disease, cell and gene therapy, and pediatric programs where in-vivo data is limited; small molecule, biologics, and biosimilar programs needing PK/PD or PBPK support; regulatory affairs teams using Pinnacle 21 for submission data standards.
• Less ideal fit: Manufacturers whose primary need is large-scale longitudinal claims or EHR cohort analytics; pair Certara with a dedicated RWD platform when patient-level data depth is the central need.
• Commercial fit: Subscription pricing for software, with services pricing layered on for consulting and submission work; confirm modular versus bundled scope and how software access scales across program teams.
• Scope diligence: Software licensing scope, regulatory references for the specific therapy area, model-governance practices, consulting team continuity, and how Certara coordinates with other RWD or HEOR partners.

Differentiators

• Regulatory-qualified biosimulation tools: Simcyp and Phoenix are referenced in FDA and EMA evaluations, creating deep switching costs once embedded in a sponsor’s submission workflow.
• MIDD breadth across the drug lifecycle: Model-informed drug development work supports 90%+ of FDA novel approvals annually, with applications across discovery, dose selection, special populations, and label expansion.
• Pinnacle 21 data standards stack: Industry-standard CDISC compliance tooling; February 2026 CRF Creator launch reduces submission start-up review cycles by 50%.
• AI-powered modeling layer: Certara.AI, D360, and Certara IQ extend the legacy biosimulation stack into AI-assisted modeling workflows for QSP and pharmacometric work.
• Market access and HEOR consulting: Standalone consulting practice for payer value dossiers, HEOR analyses, and label-strategy work alongside the modeling software business.

RFP Questions

• Which Simcyp, Phoenix, Pinnacle 21, Certara.AI, and D360 modules are included under a given subscription, and how does access scale across program teams?
• Which regulatory submissions in the target therapy area have used Certara’s MIDD or biosimulation work, and what evidence supports the reduction in clinical-trial burden?
• How does Certara coordinate with the manufacturer’s existing pharmacometrics, biostatistics, and regulatory teams during submission work?
• What model-governance, audit-trail, and reproducibility controls apply to biosimulation outputs used in regulatory submissions?
• Which HEOR and market access consulting projects in the target therapy area are recent enough to be referenceable?
• How is client-side data uploaded into Certara modeling environments governed for privacy, security, and data rights?
• What turnaround does the Expedited Pharmacometrics Regulatory Submissions service support for the target submission timeline?

Recent Activity

• 2026-05 - Current Certara materials support the 1,550-person global team, 440+ PhD bench, 90%+ FDA novel-approval involvement, 100+ novel-drug metrics, and current solution / software / services taxonomy.

• 2026-03: FDA accepted Simcyp predictions for the Novartis asciminib NDA, replacing 10 separate human clinical trials.

• 2026-02: CRF Creator launched within the Pinnacle 21 stack, reducing submission start-up review cycle by 50%.

• 2026-01: Jon Resnick appointed CEO, succeeding Dr. William F. Feehery.

• 2025-Q4: Certara IQ launched (AI-powered QSP modeling software).

• 2025-12: Expedited Pharmacometrics Regulatory Submissions service announced with 4-6 week turnaround.

• 2024: Headquarters relocated from Princeton, NJ to Radnor, PA.